Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy

Monica Merito; Paolo Giorgi Rossi; Jessica Mantovani; Filippo Curtale; Piero Borgia; Gabriella Guasticchi

doi:10.1016/j.vaccine.2006.08.005

Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy

Monica Merito, Paolo Giorgi Rossi, Jessica Mantovani, Filippo Curtale, Piero Borgia, Gabriella Guasticchi

Arcispedale Santa Maria Nuova

Research output: Contribution to journal › Article › peer-review

Abstract

Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.

Original language	English
Pages (from-to)	458-465
Number of pages	8
Journal	Vaccine
Volume	25
Issue number	3
DOIs	https://doi.org/10.1016/j.vaccine.2006.08.005
Publication status	Published - Jan 5 2007

Keywords

Cost-effectiveness analysis
Elderly
Pneumococcal polysaccharide vaccine

ASJC Scopus subject areas

Immunology
Microbiology
Virology
Infectious Diseases
Public Health, Environmental and Occupational Health
veterinary(all)

Access to Document

10.1016/j.vaccine.2006.08.005

Cite this

@article{2697664ff8a34b6f829ff241c74155a3,

title = "Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy",

abstract = "Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.",

keywords = "Cost-effectiveness analysis, Elderly, Pneumococcal polysaccharide vaccine",

author = "Monica Merito and {Giorgi Rossi}, Paolo and Jessica Mantovani and Filippo Curtale and Piero Borgia and Gabriella Guasticchi",

year = "2007",

month = jan,

day = "5",

doi = "10.1016/j.vaccine.2006.08.005",

language = "English",

volume = "25",

pages = "458--465",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy

AU - Merito, Monica

AU - Giorgi Rossi, Paolo

AU - Mantovani, Jessica

AU - Curtale, Filippo

AU - Borgia, Piero

AU - Guasticchi, Gabriella

PY - 2007/1/5

Y1 - 2007/1/5

N2 - Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.

AB - Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.

KW - Cost-effectiveness analysis

KW - Elderly

KW - Pneumococcal polysaccharide vaccine

UR - http://www.scopus.com/inward/record.url?scp=33845304311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845304311&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.08.005

DO - 10.1016/j.vaccine.2006.08.005

M3 - Article

C2 - 17049685

AN - SCOPUS:33845304311

VL - 25

SP - 458

EP - 465

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 3

ER -

Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this